| ●Editorial | Fukushima M | 5-6 | Full text | |
| ●Public Debriefing Session 2013 Emerging academia-origin medical innovation －Initiation of clinical & translational research center network－ | 7-265 | Abstract | ||
| Organized by: Ministry of Education, Culture, Sports, Science
and Technology Ministry of Health, Labour and Welfare | ||||
| ◉Ministry of Education, Culture, Sports, Science and Technology Translational Research Network Program | ||||
| Opening remarks by MEXT | Komatsu S | 15 | ||
| Opening remarks by PD | Saruta T | 16 | ||
| Report from the Support Organization | Nagai Y | 19-23 | ||
| All Hokkaido Translational Research Project for Advanced Medicine | Sato N | 27-9 | ||
| Clinical Research, Innovation and Education Center, based on collaboration between biomedical engineers and clinicians | Shimokawa H | 30-3 | ||
| Advanced center for the establishment and coordination of biomedical innovation development assistance | Saito N | 34-6 | ||
| Establishment of central Japan network for sustainable development of advanced medicine | Mizuno M | 37-41 | ||
| Reinforcement of academic base for development of novel drug and medical treatment | Shimizu A | 42-5 | ||
| Strategic promotion of core center development for TR practice | Myoui A | 46-50 | ||
| Establishment of academic research organization supporting developments of innovative medicine for the next generation | Nakanishi Y | 51-5 | ||
| Network construction | Aoki M | 59-2 | ||
| Patent/research strategies in academia | Yamanaka A | 65-8 | ||
| Intranasal vaccination with inactivated whole virions against influenza virus infection | Matano T | 71-3 | ||
| FIT039, new type of antiviral agent with targeting a host kinase | Hagiwara M | 74-6 | ||
| Development of next generation traveler’s vaccine with adjuvant stimulating innate immunity | Horii T | 77-8 | ||
| Questions and answers | 79-80 | |||
| PET Study using C-11 Methionine | Tamaki N | 81-4 | ||
| Adoptive cell therapy for refractory hematopoietic malignancy by TCR gene-engineered
T cells with next generation retroviral vectors | Shiku H | 85-8 | ||
| Promotion of an investigator-initiated clinical trial of prostate cancer treatment using a novel anti-cancer reagent | Kaneda Y | 89-92 | ||
| Verification of the anti-tumor effect of aromatic amine derivatives and acquisition of preclinical POC | Kanai Y | 93-6 | ||
| Questions and answers | 97-8 | |||
| Development of noncontact magnetic stimulation to minimize infarction size and to improve long-term prognosis | Sunagawa K | 99-102 | ||
| Questions and answers | 103 | |||
| New-generation cerebral blood flow measurement using a non-radioactive water probe for magnetic resonance imaging | Sasaki M | 104-7 | ||
| Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury | Yamashita T，Sasaki M | 108-10 | ||
| A possible therapeutic approach for neuromuscular disorders | Yamanashi Y | 111 | ||
| A fully implantable wireless system for motor and communication control based on electrocorticograms | Yoshimine T，Hirata M | 112-4 | ||
| Questions and answers | 115-6 | |||
| Clinical induction of tissue-engineered cartilage realizing the combination of the regenerative cartilage with the regenerative mucosa | Takato T | 117-20 | ||
| Development of a new drug for the treatment of inflammatory bowel diseases using probiotic-derived polyphosphate | Fujiya M | 121-4 | ||
| The development and utility of new uroflowmetry measurement by wearable airborne ultrasound Doppler system | Matsumoto S | 125-8 | ||
| Pulsed Water Jet: Medical Device to achieve maximal removal and functional preservation | Tominaga T，Nakagawa A | 129-33 | ||
| Questions and answers | 134-5 | |||
| Closing remarks | Inagaki O | 139-40 | ||
| Closing remarks | Kageyama S | 141 | ||
| ◉Ministry of Health, Labour and Welfare Early/Exploratory Clinical Trial Center Development Projects and Clinical Trials Core Hospital Development Projects | ||||
| Address of Ministry of Health, Labour and Welfare | Hara N | 145-6 | ||
| Opening remarks by PD | Saruta T | 147-8 | ||
| Annual report from PDCA Management Office | Fukushima M | 151-7 | ||
| Challenge for the cutting-edge center in oncology drug development | Ohtsu A | 161-5 | ||
| Drug development process in the area of cerebro-cardiovascular diseases at the Osaka University | Sawa Y | 166-9 | ||
| Construction of a hub academia for promoting the development of innovative medical devices | Minematsu K | 170-4 | ||
| Challenges to drug discovery for neuropsychiatric diseases in academia | Iwatsubo T | 175-8 | ||
| Early/Exploratory Clinical Trial Center Development Projects for immune-mediated intractable diseases | Takeuchi T | 179-83 | ||
| Questions and answers | 184-6 | |||
| Clinical Trials Core Hospital Development Projects of Hokkaido University Hospital | Sato N | 189-92 | ||
| Development of new therapy－Double Wing Project Composed of Creation and Science－ | Hanaoka H，Nagai E | 193-7 | ||
| A program of Nagoya University Hospital for Clinical Trials Core Hospital | Mizuno M | 198-202 | ||
| Construction of highway for clinical research in Kyoto University and
medical development for treatment of cancer and incurable diseases using the highway | Shimizu A | 203-7 | ||
| Establishment of academic research organization that provides novel and
optimal treatment and hope for the next generation | Nakanishi Y | 208-12 | ||
| Medical devices development launched from the Tohoku area | Shimosegawa T | 213-7 | ||
| Gunma University Hospital will establish Core 5 Hospitals of Clinical
Trials and Research Japan (Core 5 Hospitals CTRJ) to accelerate important clinical trials based on brand-new life-science technology | Nakamura T | 218-22 | ||
| Toward the promotion of clinical research as the Clinical Trials Core
Hospital in the National Center for Child Health and Development | Igarashi T | 223-6 | ||
| Establishment of international-standard clinical study system created by a national network | Horibe K | 227-32 | ||
| A new clinical development of Chugoku-Shikoku Area －Aiming for clinical research ‘mega hospital’ of international standards－ | Makino H | 233-7 | ||
| Questions and answers | 238-40 | |||
| Expectation for MHLW’s 5-year plan 2012 for reactivating environments of clinical studies/trials | Inagaki O | 243-6 | ||
| The point of view from a person who has moved from industry to academia | Akabori M | 247-9 | ||
| Development of drugs for intractable / rare disease will rescue Japan | Shiomura J | 250-3 | ||
| Plenary discussion | 257-62 | |||
| Closing remarks | Ichinose A | 265 | ||
| ●Instructions for authors［Japanese］＆［English］ | 267-75 | Full text | ||